【医疗健康行业周报】波士顿科学以37亿美元收购Axonics，复星凯特计划推出一CAR-T疗法的“按疗效支付”。
近日，全球领先的医疗科技公司波士顿科学宣布以37亿美元的价格收购Axonics。此次收购将进一步扩大波士顿科学的业务范围，提升其在医疗领域的竞争力。Axonics是一家专注于研发和生产创新医疗设备的公司，其产品广泛应用于心血管、神经和骨科等领域。此次收购将使波士顿科学在相关领域的技术实力得到进一步提升。
此外，复星凯特也宣布计划推出一种CAR-T疗法的“按疗效支付”模式。CAR-T疗法是一种新型的癌症治疗方法，通过改造患者自身的T细胞，使其能够识别并攻击癌细胞。然而，CAR-T疗法的费用较高，给患者带来了较大的经济负担。复星凯特推出的“按疗效支付”模式，将根据患者的治疗效果来支付费用，有望降低患者的经济压力。
英语如下：
====
“News Headline: Boston Scientific Acquires Axonics for $3.7 Billion, Fosun Pharma Launches “Pay-for-Performance” CAR-T Therapy
Keywords: Medical Acquisition, Fosun Therapy, Pay-for-Performance
News Content: [Medical Health Industry Weekly Report] Boston Scientific acquires Axonics for $3.7 billion, and Fosun Pharma plans to launch a “pay-for-performance” model for CAR-T therapy.
Recently, global leading medical technology company Boston Scientific announced its acquisition of Axonics for $3.7 billion. This acquisition will further expand Boston Scientific’s business scope and enhance its competitiveness in the medical field. Axonics is a company focused on researching and producing innovative medical devices, whose products are widely used in cardiovascular, neurological, and orthopedic fields. This acquisition will further enhance Boston Scientific’s technological strength in these related fields.
In addition, Fosun Pharma also announced its plan to launch a “pay-for-performance” model for CAR-T therapy. CAR-T therapy is a new type of cancer treatment that modifies the patient’s own T cells to enable them to identify and attack cancer cells. However, the cost of CAR-T therapy is high, which brings a heavy financial burden to patients. The “pay-for-performance” model launched by Fosun Pharma will pay based on the patient’s treatment effect, which is expected to reduce the economic pressure on patients.”
【来源】https://www.36kr.com/p/2604034727279241
Views: 1